NCT06095934View on ClinicalTrials.gov

Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

December 30, 2025

Conditions

NSCLCEGFR Gene Mutation

Interventions

OTHER

neo-antigen vaccine

anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy

Trial Locations (1)

Unknown

RECRUITING

The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Medical School of Nanjing University & Clinical Center Institute of Nanjing University, Nanjing, China, Nanjing

All Listed Sponsors

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER